Search results
2 lip 2024 · WASHINGTON (AP) — U.S. officials have approved another Alzheimer’s drug that can modestly slow the disease, providing a new option for patients in the early stages of the incurable, memory-destroying ailment.
4 maj 2023 · In May 2023, pharmaceutical company Eli Lilly & Company (Lilly) released the positive initial results of a clinical trial into a new Alzheimer’s drug, donanemab. You may also hear donanemab be called its brand name, Kisunla.
18 lip 2024 · On July 2, 2024, the U.S. Food and Drug Administration approved Kisunla (donanemab), a new Alzheimer’s medication shown to slow the progression of the disease. Join our conversation with Dr. Paul Aisen as he details how the drug works, for whom, side effects, what it costs, whether it’s covered by insurance, and how it compares with other ...
17 lip 2023 · Full results about the Alzheimer's disease drug donanemab have been released today, supporting earlier trial results that suggested the breakthrough drug may slow down the progression of the disease.
2 lip 2024 · CHICAGO, July 2, 2024 — The Alzheimer’s Association celebrates today’s U.S. Food and Drug Administration (FDA) action to approve Kisunla™ (donanemab, Eli Lilly) for the treatment of people living with early symptomatic Alzheimer’s disease, which includes mild cognitive impairment and the mild dementia stage of Alzheimer’s disease ...
2 lip 2024 · The Food and Drug Administration on Tuesday approved a new drug for Alzheimer’s disease, the latest in a novel class of treatments that has been greeted with hope, disappointment and...
2 lip 2024 · The Food and Drug Administration approved Eli Lilly’s Kisunla on Tuesday for mild or early cases of dementia caused by Alzheimer’s. It’s only the second drug that’s been convincingly...
